Pharmacologic inhibition of vein graft neointimal hyperplasia  by Schachner, Thomas
P
h
T
Schachner Surgery for Acquired Cardiovascular Diseaseharmacologic inhibition of vein graft neointimal
yperplasiahomas Schachner, MD
A
o
i
m
t
l
s
c
u
(
i
r
I
e
a
o
h
F
i
A
g
e
t
s
o
e
3
u
(
l
t
t
f
g
o
A
CDFrom the Department of Cardiac Surgery,
Innsbruck Medical University, Innsbruck,
Austria.
Received for publication Sept 9, 2005; ac-
cepted for publication Nov 16, 2005.
Address for reprints: Thomas Schachner,
MD, Anichstrasse 35, 6020 Innsbruck,
Austria (E-mail: Thomas.Schachner@uibk.
ac.at).
J Thorac Cardiovasc Surg 2006;131:1065-72
0022-5223/$32.00
Copyright © 2006 by The American Asso-
ciation for Thoracic Surgery
Dr Schachnert
doi:10.1016/j.jtcvs.2005.11.043
Tlthough arterial conduits are widely used and have improved the long-term results
f coronary artery bypass grafting, vein grafts remain important additional conduits
n coronary surgery. Newer studies show a saphenous vein graft patency of 60% or
ore at 10 years postoperatively. The pathology of vein graft disease consists of
hrombosis, neointimal hyperplasia, and vein graft atherosclerosis, which limit graft
ongevity. Therapeutic strategies to prevent vein graft disease include external
tenting, pharmacotherapy, and gene therapy. The potential benefits of a pharma-
ologic approach are as follows: (1) Drugs with a broad clinical experience can be
sed; (2) side effects of systemic application can be minimized by local therapy; and
3) no vascular injury, such as pressurizing the vein for a viral transfection approach,
s necessary. The different sites for pharmacotherapy in vein graft disease are
eviewed in this article.
n addition to the use of arterial bypass conduits, vein grafts still play an
important role in coronary surgery. Newer studies show a saphenous vein graft
patency of 60% or more at 10 years postoperatively.1-3 There seems to be an
qual or even increased patency over decades despite the generally increased age
nd comorbidity of the patient population. One can hypothesize that this is the result
f an increased awareness of vein graft disease. In addition, a more refined technical
andling, influenced by the knowledge in arterial grafting, may have occurred.
urthermore, better postoperative care (eg, early aspirin, statins, cessation of smok-
ng, blood pressure lowering) may contribute to increased vein graft longevity.
ngiographic follow-up studies demonstrated equal long-term patency rates of vein
rafts to the right coronary artery compared with internal thoracic artery grafts,
specially when the target vessel stenosis was less than 70%.4-6
Neointimal hyperplasia (NIH) is a typical pathologic feature of vein grafts during
he first weeks after arterialization. It is thought that NIH eases vein graft athero-
clerosis, which occurs during several years after grafting and leads to stenosis and
cclusion of the vein grafts (Figure 1).7-9
Reasons for an immediate injury of the vein are surgical trauma, ischemia,
ndothelial injury, and increased wall stress after arterialization. After an early (first
–5 days) medial smooth muscle cell (SMC) loss (caused by apoptosis), a consec-
tive increase of total vascular wall thickness occurs.10,11
NIH results from cellular proliferation (SMC, myofibroblasts), cell migration
SMC from the media, myofibroblasts from the periadventitia, macrophages from
uminal and adventitial side, platelets from luminal side), extracellular matrix deposi-
ion, and inflammatory processes (leukocytes, platelets, growth factors, cytokines).
The source of cells in the hyperplastic vein graft is of importance in the attempt
o prevent vein graft disease. In LacZ-expressing mice, Zhang and colleagues12
ound that approximately 60% of cells in the vein graft neointima developed from
raft-extrinsic precursors. Another experiment using decellularized vein grafts dem-
nstrated that vein graft-extrinsic cells can form a neointima.13
Hu and colleagues14 used SM-LacZ transgenic mice (which express beta galac-
osidase in SMCs) and found that 40% of SMCs in vein grafts were graft-extrinsic
he Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 5 1065
cp
a
s
o
c
c
N
p
a
l
t
m
v
e
h
r
c
r
g
s
a
a
o
c
n
i
d
m
i
s
i
T
d
1
v
w
i
p
g
fi
Surgery for Acquired Cardiovascular Disease Schachner
1
A
CDells and that 60% were graft-intrinsic cells at 8 weeks
ostoperatively.14 In another study,15 the potential role of
dventitial progenitor cells for vein graft NIH was demon-
trated. In another mouse model,16 predominantly recipient
rigins of endothelial cells (with one third of endothelial
ells of vein grafts derived from bone marrow progenitor
ells) were found in vein grafts.
The adventitia also has a clear role in the development of
IH. For example, one third of periadventitial cells were
ositive for proliferating cell nuclear antigen early after
rterialization in a pig model.17 In addition, Shi and col-
eagues18 demonstrated labeled fibroblasts migrating from
he periadventitial space into the vein graft wall.
Convincing evidence exists for the role of migrating
onocytes/macrophages on the inflammatory features of
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CABG  coronary artery bypass graft
ET  endothelin
ICAM-1 intercellular adhesion molecule-1
MMP matrix metalloproteinase
NIH  neointimal hyperplasia
NO  nitric oxide
ODN  oligodeoxynucleotide
PDGF  platelet-derived growth factor
PGI2  prostacyclin
SMC  smooth muscle cell
TIMP  tissue inhibitor of metalloproteinase
VSMC  vascular smooth muscle cell066 The Journal of Thoracic and Cardiovascular Surgery ● Maein graft disease.19 Cross and colleagues20 found the pres-
nce of mast cells (an important source of cytokines such as
istamine, leukotriene C4, and platelet-activating factor) in
abbit vein grafts 4 weeks postoperatively, whereas no mast
ells were found in ungrafted veins.20
Intercellular adhesion molecule (ICAM)-1 is a counter-
eceptor that is engaged in leucocyte adhesion and transmi-
ration, and that is abundantly present on the endothelial
urface of mouse vein grafts 4 weeks after surgery. Zou
nd colleagues21 observed a decreased leucocyte amount
nd a 40% reduced neointimal thickness in ICAM-1 knock-
ut mice compared with wild-type animals. Crook and
olleagues22 found an increase in ICAM-1 in human saphe-
ous veins cultured for 14 days compared with freshly
solated veins. In the same study the ICAM-1 amount was
ramatically increased after a 24-hour incubation with tu-
or necrosis factor-, interleukin-1, and interferon-.22
In low-flow vein grafts (poor distal runoff), the neo-
ntimal thickness was markedly increased and the mes-
enger ribonucleic acid expression of the proinflammatory
nterleukin-1 was greater than in high-flow vein grafts.23,24
he increased vein graft patency in good runoff areas is also
ocumented clinically. Goldman and colleagues2 found a
0-year patency of saphenous vein graft of 88% in target
essels greater than 2.0 mm diameter versus 55% in vessels
ith diameters 2.0 mm or less.2
Vein graft atherosclerosis occurs after several years and
s difficult to achieve in animal models. However, it is in
art possible to find features of graft atherosclerosis in vein
rafts of animals with hyperlipidemia. Atheromas with in-
ltrating mononuclear cells, foam cells, cholesterol crystals,
Figure 1. Different grades of saphenous vein
graft atherosclerosis in the same patient 9
years after CABG. Parts without calcifications
(A), intramural calcifications (B), superficial
calcifications (C), and calcifications involving
large parts of the vascular wall (D). *Areas of
calcification (hematoxylin-eosin stain).y 2006
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CDnd calcified necrotic cores and areas of necrosis in the
ascular wall have been found in vein grafts of apolipo-
rotein E-deficient (hypercholesterolemic) mice.25 In hyper-
holesterolemic rabbits, NIH was markedly increased and
ontained lipid vacuoles, and foam cells compared with
hose of normocholesterolemic rabbits at 4 weeks after
peration.26,27 Grafts of hypercholesterolemic rabbits ex-
ibited a significantly increased (contractile) sensitivity to
erotonin and decreased (vasodilatory) sensitivity to sodium
itroprusside compared with vein grafts of normocholester-
nemic rabbits.28
The prevention of vein graft NIH starts with careful “no
ouch” harvesting and a short ischemic time. In arterialized
ouse jugular vein patches, Sakaguchi and colleagues29
emonstrated an increased neointimal area in vein patches
tored for 2 hours before grafting compared with immedi-
tely grafted vein patches. Furthermore, the increased stor-
ge time was associated with a decreased cyclic adenosine
onophosphate amount in the veins.29
Vein graft disease can be studied clinically or experi-
entally (SMC culture, saphenous vein organ culture, and
nimal models). Experimentally, veins have been treated
ith external stenting, pharmacologic therapy, or gene ther-
py to attenuate neointimal formation. However, only a few
ethods for prevention of vein graft failure, such as the
se of aspirin, lipid-lowering drugs (especially statins), and
essation of smoking, have reached clinical practice.
Promising results have been achieved with the use of
2F decoy in vascular surgery, but thus far no benefit has
een shown in patients who underwent coronary artery
ypass grafting (CABG).30 The potential benefits of a phar- c
The Journal of Thoracicacologic approach are as follows: (1) Drugs with a broad
linical experience can be used, (2) side effects of systemic
pplication can be minimized with local therapy, and (3) no
ascular injury such as pressurizing the vein for a viral trans-
ection approach is necessary. Hu and colleagues31 demon-
trated that local application of adenovirus vector resulted in
nhanced inflammatory response and NIH in mouse vein
rafts at 4 and 8 weeks postoperatively. With a pharmaco-
ogic approach there is no transfection virus-mediated in-
ammatory response in the vascular wall.
One of the major disadvantages of local pharmacother-
py is the limited duration of action, which may be im-
roved by suitable carriers.
pecial Sites of Pharmacologic Intervention to
revent Neointimal Hyperplasia Thrombosis
n mouse vein grafts, mural fibrin deposits and thrombus
ormation (with a maximum at 1-3 days postoperatively)
ere found during the first week after arterialization
Figure 2).32,33 Thrombomodulin, by binding thrombin
which thereby loses its fibrinogen cleaving capacity and
ains protein C-activating ability), is important for the en-
othelial thromboresistance. Kim and colleagues34 demon-
trated a decrease of thrombomodulin in rabbit vein grafts
f less than 10% of the amount of ungrafted veins within the
rst 2 weeks postoperatively. Tissue factor is a transmem-
rane glycoprotein that activates factor VII and leads to
ncreased thrombin production. Channon and colleagues35
ound an increased amount of tissue factor in rabbit vein
rafts, which was spatially associated with infiltrating leu-
Figure 2. Overview of pharmacotherapeutic
approaches to prevent vein graft neointimal
hyperplasia. bFGF, Basic fibroblast growth fac-
tor; cAMP, cyclic adenosine monophosphate;
cGMP, cyclic guanosine monophosphate; ERK,
extracellular signal-regulated kinase; IGF,
insulin-like growth factor; IL, interleukin; JNK,
c-jun N-terminal kinase; MAPK, mitogen-
activated protein kinase; mTOR, mammalian
target of rapamycin; NF, nuclear factor;
PCNA, proliferating cell nuclear antigen; TNF,
tumor necrosis factor.ocytes early after arterialization. The same group, how-
and Cardiovascular Surgery ● Volume 131, Number 5 1067
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CDver, noticed no benefit of locally applied antitissue fac-
or antibody regarding the development of NIH.36 Both
ocal and systemic treatment with aspirin reduced throm-
us formation and NIH in animal experiments of vein
raft disease.33,37 C-type natriuretic peptide inhibits vascu-
ar smooth muscle cell (VSMC) proliferation and shows anti-
nflammatory and antithrombotic effects. Local application
f C-type natriuretic peptide decreased NIH in mouse vein
rafts. In the same study the amount of adventitial CD8
eukocytes was decreased in C-type natriuretic peptide-
reated vein grafts compared with controls.38 In addition to
ntithrombotic properties, heparin inhibits SMC prolifera-
ion in vitro and inhibits neointimal thickening in injured
rteries. However, heparin treatment of rats (800 U/12 h for
days subcutaneously) failed to suppress NIH at 2 weeks
ostoperatively.39
eactive Oxygen Species
eactive oxygen species (eg, superoxide anion, peroxide,
ydroxyl radical) are constantly generated in aerobic life,
ut unusually high amounts are found in activated leuko-
ytes and after tissue hypoxia. Malondialdehyde, a marker
or lipid peroxidation, was more than 5-fold increased in vein
rafts 3 days postoperatively compared with ungrafted veins.
ntioxidative treatment with polyethylene glycolated super-
xide dismutase (vein immersed in polyethylene glycol-
uperoxide dismutase for 15 minutes and perivascular ap-
lication in Pluronic gel) reduced both malondialdehyde
oncentrations in grafts at 3 days postoperatively and NIH
t 4 weeks postoperatively.40 Treatment of rabbits with the
ntioxidant methylaminochroman (10 mg · kg · d by mouth)
howed an increased preservation of vein graft vasorelax-
tion after acetylcholine and sodium nitroprusside exposure
t 4 weeks postoperatively compared with controls. Mor-
hologically the vein grafts of methylaminochroman-treated
nimals exhibited a reduced NIH compared with controls.41
itric Oxide and Prostacyclin
itric oxide (NO) and prostacyclin (PGI2) exhibit anti-
hrombotic, vasodilatory, and antiproliferative (PGI2) prop-
rties. Early after arterialization, NO, PGI2, and their sec-
nd messengers cyclic guanosine monophosphate and cyclic
denosine monophosphate are reduced in porcine vein
rafts.42,43 Onohara and colleagues44,45 demonstrated a de-
reased stimulated (with arachidonic acid) PGI2 production
n canine vein grafts with a poor runoff and low shear stress
ompared with veins grafted into a good runoff area. The
ow dependency of vein graft disease was confirmed by the
act that vein grafts with poor distal runoff showed in-
reased (approximately doubled) NIH compared with con-
rol vein grafts. Rabbit vein grafts instilled for 15 minutes
ith 100 mol/L L-arginine show increased NO levels, andt 4 weeks postoperatively they exhibit a reduced neointi- T
068 The Journal of Thoracic and Cardiovascular Surgery ● Maal formation.46 A similar attenuation of NIH can be ob-
ained by perivascular application of spermine/NO as NO
onor.47 In hypercholesterolemic rabbits, L-arginine (2 g/kg,
y mouth) treatment led to a 24% reduction of neointimal
hickness.48
After precontraction with phenylephrine, human saphe-
ous veins did not relax with aspirin, but they did relax with
itroaspirins and sodium nitroprusside (NO donor). Ni-
roaspirins and sodium nitroprusside increased the tissue
yclic guanosine monophosphate amount, whereas aspirin
id not increase cyclic guanosine monophosphate in fresh
uman saphenous vein organ cultures.49
ndothelin
ndothelin (ET)-1 is a 21 amino acid peptide with vasocon-
ractile and VSMC mitogenic properties (Figure 3). ET-1 is
roduced as inactive precursor big ET-1 (38 amino acids) in
ascular endothelial cells, which is activated by cleavage by
he metalloproteinase endothelin-converting enzyme. Porter
nd colleagues50 demonstrated that nonselective ET recep-
or antagonism with bosentan and ET receptor B antago-
ism with BQ788 reduced NIH in human saphenous vein
ultures, whereas the selective ET receptor A antagonist
Q123 failed to reduce neointimal formation.50 The same
roup found in another study51 that the neutral endopepti-
ase inhibitor CGS 24592 increases NIH by approximately
5% in cultured saphenous veins. This augmentation of
IH was associated with an increased amount of ET-1 (by
locking its degradation). On the other hand, treatment with
GS 26303, an inhibitor of both neutral endopeptidase and
ndothelin-converting enzyme, had no effect on neointimal
hickness. Wan and colleagues52 demonstrated a reduced
eointimal thickness in porcine vein grafts by oral treatment
ith the ET-1A receptor antagonist BSF 302146. Dash-
ood and colleagues53 found ET-A receptors abundantly
resent in ungrafted porcine saphenous veins, which was
ven higher than in grafted veins 4 weeks after implantation.
T-B receptors were found to a lesser extent in the media
ut more frequently in the adventitial microvasculature.
igure 3. Influence of pharmacologic intervention in the endothe-
in system on vein graft NIH. ECE, Endothelin-converting enzyme.his suggests a susceptibility of the vein for VSMC mito-
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A
CDenic effects of ET 1, which is increased after mechanical
all stress.
latelet-Derived Growth Factor
rom various growth factors, platelet-derived growth factor
PDGF) (which is released by activated platelets, monocytes,
nd SMCs) is thought to play a key role in restenosis of
njured arteries.54 In a pig model, Francis and colleagues55
ound higher messenger ribonucleic acid levels for PDGF in
ein grafts than in ungrafted veins. PDGF and other cyto-
ines (basic fibroblast growth factor, interleukin-1, and tu-
or necrosis factor-) are increased during the develop-
ent of NIH in rat vein grafts.56,57 Huang and colleagues58
emonstrated a dose-dependent augmentation of NIH in sa-
henous veins when PDGF was added to the culture me-
ium. Receptors for PDGF, endothelial growth factor, and
asic fibroblast growth factor exhibit an intrinsic ligand-
timulated tyrosine kinase activity. Local treatment of
abbit vein grafts with tyrphostin AG51, a tyrosine kinase
nhibitor, led to an approximately 50% reduction of neoin-
imal thickness 4 weeks postoperatively. Tyrphostin-treated
ein grafts showed no contractile response to norepineph-
ine, whereas control vein grafts contracted.59 Suramin is a
rowth factor (especially PDGF) receptor antagonist. In a
ouse model, local treatment of veins with suramin led to
ore than a 50% reduction of neointimal thickness 4 and 8
eeks postoperatively compared with controls. In the same
tudy suramin treatment was associated with a decreased
mount of PDGF and PDGF receptors in neointimal
MCs compared with control vein grafts.60
ngiotensin
ngiotensin II is generated from angiotensin I by angiotensin-
onverting enzyme (ACE) and chymase, which are present
n the vascular tissue (Figure 4). Yuda and colleagues61 dem-
nstrated a 10-fold chymase activity and a doubled ACE
ctivity in grafted veins compared with control veins 4
eeks postoperatively. In animal experiments,62 angioten-
in II accelerated atherosclerosis and even aneurysmal dis-
ase. Systemic treatment of rabbits with the ACE inhibitor
aptopril (10 mg · kg · d, by mouth) reduced NIH by 40% at
 weeks postoperatively.63 However, the effects of ACE
nhibitors are influenced by 2 important factors: (1) the
ascular chymase activity and (2) the tissue penetration of
he ACE inhibitors, which vary from low (eg, enalapril) to
igh (eg, quinapril).61,64 Local therapy of veins with the
hymase inhibitor Suc-Val-Pro-Phe-(OPh)2 for 20 minutes
as been shown to inhibit neointimal formation and total
ngiotensin II-forming activity until 3 months after opera-
ion in dogs.65 In 2 studies the systemic treatment (10
g · kg · d, by mouth) with the angiotensin II antagonist
-158,809 led to a significant decrease of NIH.61,66 Localreatment of rabbit vein grafts with L158809 reduced neo- m
The Journal of Thoracicntimal thickness by 33%, whereas the medial thickness was
ot different from controls at 4 weeks postoperatively.
here was a contractile response to angiotensin of controls
nd locally treated vein grafts (at 4 weeks postoperatively),
hereas there was no contractile reaction after angiotensin
timulation in systemically L158809 treated vein grafts.66
atrix Metalloproteinases
atrix metalloproteinases (MMPs) are zinc-dependent en-
ymes that mediate matrix degradation and deposition. For
he development of NIH, SMC hyperplasia and migration
re key events that require the degradation of matrix pro-
eins and the elastic laminae.67 In 2 days of organ culture
egments of porcine veins 1 to 4 weeks after bypass grafting
roduced significantly more (pro-) MMPs (pro-MMP9, pro-
MP2, active MMP2) compared with ungrafted veins as
easured by zymography. Immunohistochemically, MMP2
as found in the neointima 1 to 4 weeks postoperatively,
nd MMP9 was localized in the neointima and media start-
ng from day 2 (and increased until day 28) after bypass
rafting.68 The physiologic antagonists of the MMPs are
erine proteases and specific tissue inhibitors of metallopro-
einases (TIMPs). Treatment with the broad-spectrum MMP
nhibitor marimastat led to a reduced NIH in cultured hu-
an saphenous veins that was paralleled by a significant
eduction in the levels of MMP-2 and MMP-9 in the tis-
ues.69 Treatment of cultured veins with doxycycline (10
g/mL) also led to a reduction of NIH that was associated
ith a reduced MMP-9 amount (gelatin zymography). How-
ver, there was no difference in the amounts of MMP-2,
IMP-1, and TIMP-2 between doxycycline-treated veins
nd controls.70
Statins inhibit 3-hydroxy-3 methylglutaryl coenzyme A
eductase and thereby decrease mevalonic acid. The con-
equences are not only a cholesterol-lowering effect but
lso so-called pleiotropic effects (eg, inhibition of SMC
igure 4. Potential pharmacologic attenuation of vascular angio-
ensin II effects.igration and proliferation, increase of NO and decrease of
and Cardiovascular Surgery ● Volume 131, Number 5 1069
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A
CDT-1 in endothelial cells, inhibition of MMPs).71 Simvasta-
in attenuated NIH in cultured human saphenous veins,
hich was reversed with additional application of meval-
nate. Furthermore, simvastatin treatment led to a reduction
f MMP-9, but not MMP-2, in the vascular tissue.72
alcium
alcium is important for a number of cellular events includ-
ng platelet aggregation, PDGF release, and SMC prolifer-
tion. Calcium-channel blockers have been reported to in-
erfere with PDGF-induced VSMC proliferation in vitro.
erapamil, applied in a periadventitial matrix, reduced NIH
nd balanced the increased sensitivity to serotonin in hy-
ercholesterolemic rabbit vein grafts.73 El-Sanadiki and col-
eagues74 observed a significant reduction of NIH in vein
rafts of rabbits treated systemically with verapamil (1.25
g/d intravenously) at 4 weeks postoperatively compared
ith controls. The vein grafts of verapamil-treated animals
howed an increased contractile sensitivity to norepineph-
ine and histamine.
Proteins
proteins bind the guanine nucleotides GDP and GTP with
he G- subunit that carries the effector site (eg, stimulation
r inhibition of adenylyl cyclase, activation of phospho-
ipase C).
Davies and colleagues75 found a continuous increase of
protein- subunits 4 weeks after vein graft arterialization.
onoterpenes exert a cytostatic effect by inhibiting post-
ranslational isoprenylation of guanine nucleotide binding
roteins. Perillyl alcohol (200 mg · kg · d, by mouth) treat-
ent led to a 22% reduction of neointimal thickness at 4
eeks postoperatively compared with controls.76
itogen-Activated Protein Kinases
itogen-activated protein kinases are ultimate mediators
f extracellular stimuli between the cytoplasm and the
ucleus of a cell. Saunders and colleagues77 found that
xtracellular signal-regulated kinase-1/2 and p38 mitogen-
ctivated protein kinase (but not c-jun N-terminal kinases)
ere activated in dog jugular vein grafts during the first
ostoperative days compared with contralateral ungrafted
ugular veins. Yamashita and colleagues78 demonstrated the
ctivation of extracellular signal-regulated kinase-1/2, c-jun
-terminal kinase-1, and p38, which were doubled at 4 to 7
ays postoperatively compared with ungrafted veins.
ranscription and Translation
rowth factor-mediated cellular stimulation is typically fol-
owed by activation of immediate early genes. Suggs and
olleagues79 found a 5-fold increase of c-fos protein and a
0-fold increase of c-jun protein 15 minutes after vein graft
rterialization, which peaked after 2 to 6 hours and de-
070 The Journal of Thoracic and Cardiovascular Surgery ● Mareased during the following days. Local treatment of
orcine veins with antisense oligonucleotides complemen-
ary to the messenger ribonucleic acid of c-myc showed a
ignificant reduction of neointimal thickness 3 months post-
peratively.80 Suggs and colleagues showed that local treat-
ent of the rat veins with c-fos and c-jun antisense oligode-
xynucleotide (ODN) (in pluronic gel) decreased NIH,
hich was unfortunately associated with an aneurysmal
ilatation of 4 of 20 vein grafts. Both transcription factors
uclear factor-kappa B and E2F were successfully targeted
y decoy ODNs to prevent vein graft NIH. In addition, the
roliferating cell nuclear antigen amount was reduced in
ranscription factor decoy ODN-treated vein grafts com-
ared with controls.81,82 In E2F decoy ODN-treated vein
rafts of hypercholesterolemic rabbits, the atherosclerotic
esions (which were common in controls) were inhibited in
reated grafts.82
The antiproliferative properties of rapamycin are par-
ially caused by an inhibition of the serine/threonine protein
inase mammalian target of rapamycin. We demonstrated a
ose-dependent reduction of neointimal thickness with peri-
ascularly applied rapamycin in mouse vein grafts com-
ared with controls.83 Another study showed that treatment
ith rapamycin was associated with an increased apoptotic
ate in grafted veins.84
uture Perspectives
harmacologic inhibition of in-stent restenosis is commonly
sed in drug-eluting coronary stents.85,86 All of these sub-
tances used as a stent coating are of potential interest in the
revention of vein graft NIH. In general, all antiproliferative
rugs (including immunosuppressive agents) have to be
onsidered for vein graft pharmacotherapy. Systemic treat-
ent with statins, ACE inhibitors, and angiotensin II recep-
or antagonists could be optimized with regard to the indi-
idual pleiotropic effects and tissue permeability of the
ubstances.
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